



8 November 2013

Company Announcements Office
Australian Stock Exchange Level 6,
20 Bridge Street Sydney NSW 2000

Anteo and BBI Solutions Sign Heads of Terms (HoT)

- HoT signed with BBI Solutions, a global leader in immunoassay development and manufacturing services
- Anteo and BBI to collaborate on a project investigating the manufacturing and performance benefits of Mix&Go™ on BBI particles
- Commercial agreement is the anticipated outcome

8th November 2013: Anteo Diagnostics Limited (ASX: ADO) is pleased to announce that the company has entered into a Heads of Terms (HoT) with BBI Solutions (“BBI”).

Anteo and BBI will together investigate the manufacturing and performance benefits of Anteo’s Mix&Go technology on BBI particles used in lateral flow applications. It is a paid project, building on previous work and will progress in agreed phases.

Anteo and BBI expect the HoT will lead to a commercial agreement on successful completion of the Project. The specific deliverables, milestones and timelines are agreed.

“BBI has been interested in the benefits that may come from the use of Mix&Go in our systems for some time now,” said BBI Solutions’ Managing Director Fiona Marshall. “Our earlier collaborative study has supported an assertion that Mix&Go may become part of our exciting portfolio of nanoparticles.”

Anteo’s Chief Executive Officer, Dr Geoff Cumming, said, “We are pleased to continue our fruitful collaboration with BBI and hope to play a part in ensuring their continued prominence in the global Point of Care diagnostics market. We are confident that the project will be successful and progress to a binding commercial agreement. This project is another step to achieving our objective of establishing Mix&Go as the preferred solution for binding proteins in diagnostics.”

About Anteo: Anteo Diagnostics (ASX:ADO) is a surface coating company with a proprietary family of enabling chemistries called Mix&Go. Mix&Go enables the fast and easy production of superior surfaces for the biotechnology, diagnostics and pharmaceutical industries.

About BBI: BBI Solutions is part of the Alere group of companies. The BBI Group has been a trusted partner to some of the world’s foremost diagnostic and healthcare organisations for over 25 years, and has developed a leading reputation in delivering innovative solutions to partners, particularly at the point-of-care.

Founded upon the success of superior quality and performance of gold reagents, BBI has expanded to incorporate a full development and manufacturing service successfully delivering over 250 projects since inception. BBI has since grown its services further with the incorporation of a range of

Anteo Diagnostics Limited ABN 75 070 028 625

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 Fax 07 3219 0553 Email contact@anteodx.com Web www.anteodx.com



anteo diagnostics
limited

diagnostic enzymes and clinical biological reagents. The BBI Group consists of 3 divisions that deliver excellence in diagnostic assay services and products across a range of sectors, together with the supply of market-leading consumer healthcare products.

For more information visit: www.the-bbigroup.com

ENDS

For More Information Contact:

Dr Geoff Cumming, CEO
Anteo Diagnostics Limited
Tel: +61 2 8823 3110

Sam Sloane
Six Degrees Investor Relations
Tel: +61 2 9230 0661

Anteo Diagnostics Limited ABN 75 070 028 625

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

Phone 07 3219 0085 **Fax** 07 3219 0553 **Email** contact@anteodx.com **Web** www.anteodx.com

For personal use only